Empasiprubart is under clinical development by Argenx and currently in Phase II for Delayed Graft Function (DGF). According to GlobalData, Phase II drugs for Delayed Graft Function (DGF) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Empasiprubart LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Empasiprubart overview

ARGX-117 (PRO-02) is under development for the prevention of ischemia-reperfusion damage and antibody-mediated diseases like autoimmune hemolytic anemia (AIHA), antibody-mediated rejection (AMR) following organ transplantation, delayed graft function and dermatomyositis, multifocal motor neuropathy. It is administered through the intravenous route. It acts by targeting complement C2 cascade. The therapeutic candidate is a monoclonal antibody equipped with Argenx’s proprietary Fc engineering technology NHance.
It was also under development for acute respiratory distress syndrome (ARDS) in COVID-19 patients and kidney diseases.

Argenx overview

Argenx is an immunology company that developed human antibody products for autoimmune diseases. The company’s product includes VYVGART, a neonatal Fc receptor blocker, which is used to treat generalized myasthenia gravis in adults. The company’s pipeline products include Efgartigimod, ARGX-117, Cusatuzumab, ARGX-118 and ARGX-119. Argenx in partnership with Leo Pharma, AgoMab, AbbVie and Staten has been licensed to develop products such as ARGX-112, ARGX-114 and ARGX-115. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands, the United States, Japan, Switzerland and Belgium. Argenxis headquartered in Amsterdam, Noord-Holland, the Netherlands.

For a complete picture of Empasiprubart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.